Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

What Are Best Practices in Literature Monitoring for Top-performing Pharma Companies?

Posted on June 14th, 2017 by in Pharmacovigilance

The health and safety of patients is of utmost concern to pharmaceutical companies, and strict regulatory requirements ensure that safety standards remain high. But pharmacovigilance becomes an ever more difficult and overwhelming practice Continue reading “What Are Best Practices in Literature Monitoring for Top-performing Pharma Companies?” »

Shouldn’t pharmacovigilance be less painful?

Posted on May 26th, 2017 by in Pharmacovigilance

PV white board

Even with advanced information technologies, too many companies and pharmacovigilance practitioners are still living with the pain of having to rely on ineffective and outdated systems and processes. Continue reading “Shouldn’t pharmacovigilance be less painful?” »

Building a balanced search formula for pharmacovigilance and literature monitoring

Posted on March 21st, 2017 by in Pharmacovigilance

Adverse drug reactions are an important risk for patient safety and have significant impact on the costs of health systems. A rise in number of diseases has consequently led to a rise in number of drug consumption, which has also brought about an increase in the number of adverse drug events and drug toxicity cases. Continue reading “Building a balanced search formula for pharmacovigilance and literature monitoring” »

Building PV SOPs: Where to start?

Posted on March 17th, 2017 by in Pharmacovigilance

Having a set of operating standards defined through Quality Documents (QDs) is the only route to compliance and performance. QDs are defined as documents such as Policies, SOPs, Work Instructions (WINs), Manuals, Charters and Memo to File. Continue reading “Building PV SOPs: Where to start?” »

  1. 1
  2. 2
  3. 3